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In 2008, the Society for Vascular Surgery published guidelines for the treatment of carotid bifurcation stenosis. Since
that time, a number of prospective randomized trials have been completed and have shed additional light on the best
treastment of extracranial carotid disease. This has prompted the Society for Vascular Surgery to form a committee to
update and expand guidelines in this area. The review was done using the GRADE methodology.
The committee recommends carotid endarterectomy (CEA) as first line treatment for most symptomatic patients with
stenosis 50% to 99% and asymptomatic patients with stenosis 60% to 99%. The perioperative risk of stroke and death in
asymptomatic patients must be below 3% to ensure benefit for the patient. Carotid artery stenting (CAS) should be
reserved for symptomatic patients with stenosis 50% to 99% at high risk for CEA for anatomic or medical reasons. CAS
is not recommended for asymptomatic patients at this time. Asymptomatic patients at high risk for intervention or with
<3 years life expectancy should be considered for medical management as first line therapy.
In this Executive Summary, we only outline the specifics of the recommendations made in the six areas evaluated. The
full text of these guidelines can be found on the on-line version of the Journal of Vascular Surgery at http://
journals.elsevierhealth.com/periodicals/ymva. (J Vasc Surg 2011;54:832-6.)
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aCarotid endarterectomy (CEA) has been a cornerstone of
stroke prevention for five decades, and has been the subject of
extensive clinical investigation, including multiple controlled
randomized trials. The appropriate treatment of patients with
carotid bifurcation disease is of major interest to the commu-
nity of vascular surgeons. Over the last decade, carotid artery
stenting (CAS) has emerged as an alternative therapy for
treatment of carotid bifurcation stenosis. In 2008, the Society
for Vascular Surgery (SVS) published guidelines for treatment
of carotid artery disease. At the time, only one randomized
trial, comparing carotid endarterectomy and carotid stenting
had been published. Since that publication, four major ran-
domized trials comparing carotid endarterectomy and carotid
stenting have been published. These trials have further clari-
fied the relative indications for CEA and CAS, and have
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832efocused attention on the medical management of carotid
ifurcation disease. The publication of these trials has
rompted the SVS to update its 2008 recommendations. The
urrent publication expands the scope of the 2008 guidelines
o include recommendations on: imaging in identification and
haracterization of carotid stenosis, medical therapy (both as
tand-alone management and in conjunction with interven-
ion in patients with carotid bifurcation stenosis), risk stratifi-
ation to select patients for appropriate interventional man-
gement (CEA or CAS), technical standards for performing
EA and CAS, the relative roles of CEA and CAS, and
anagement of unusual conditions associated with extracra-
ial carotid pathology. The committee reviewed the extant
iterature and made recommendations after extensive discus-
ion using the GRADE system, as has been done with other
VS guidelines documents. The recommendations made in
his document represent the unanimous opinion of the com-
ittee in each instance. Recommendations are characterized
s strong grade 1 or weak grade 2, based on the quality of
vidence, the balance between desirable effects and undesir-
ble ones, the values and preferences, and the resources and
osts. Grade 1 recommendations are meant to identify prac-
ices where benefit clearly outweighs risk. These recommen-
ations can be made by clinicians and accepted by patients
ith a high degree of confidence. Grade 2 recommendations
re made when the benefits and risks are more closely matched
nd aremore dependent on specific clinical scenarios. In general,
hysician and patient preference plays a more important role in
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to the GRADE of recommendation, the level of evidence to
support the recommendation is noted. Evidence is divided into
three categories: A (high quality), B (moderate quality), and C
(low quality). Conclusions based on high quality evidence is
unlikely to change with further study, those based on moderate
quality evidence are more likely to be effected by further investi-
gation, and those based on low quality evidence are the least
supported by current data and the most likely to be subject to
change in the future. It is important to note that a grade 1
recommendationcanbemadebasedon lowquality (C)evidence
basedon the effect onpatientoutcome.For example,while there
are little data on the efficacy of CEA in asymptomatic patients
with 60% stenosis, one can recommend with confidence that
CEA not be performed in this group of patients.
Recently, the SVS was a cosponsor of recommenda-
tions made by a multispecialty group under the leadership
of the American Heart Association and the American Col-
lege of Cardiology. This extensive document represents an
effort to evaluate the existing literature on extracranial
carotid and vertebral disease and is an important reference.
For the purposes of this review, the committee placed the
highest priorities on reducing overall stroke risk, periproce-
dural stroke risk, and periprocedural mortality. Lesser impor-
tance was given to reducing nonfatal myocardial infarction,
cost, and the ability to perform a percutaneous procedure.
I. RECOMMENDATIONS FOR THE USE OF
CAROTID BIFURCATION IMAGING
(1) Imaging of the cervical carotid artery is recommended in
all patients with symptoms of carotid territory ischemia.
This recommendation is based on the significant inci-
dence of clinically relevant carotid stenosis in this patient
group and the efficacy of carotid endarterectomy (CEA)
for clinically significant lesions in reducing overall stroke
(Grade 1, level of evidence A).
(2) Imaging should be strongly considered for patients
who present with amaurosis fugax, evidence of retinal
artery embolization on fundoscopic examination, or
asymptomatic cerebral infarction and are candidates for
CEA. This recommendation is based on the interme-
diate stroke risk in this group of patients and the
efficacy of CEA in reducing risk of subsequent stroke
(Grade 1, level of evidence A).
(3) Routine screening is not recommended to detect clini-
cally asymptomatic carotid stenosis in the general popu-
lation. Screening is not recommended for presence of a
neck bruit alone without other risk factors. This recom-
mendation is based on the lowprevalence of disease in the
population at large, including those with neck bruits, as
well as the potential harm of indiscriminate application of
carotid bifurcation intervention to a large number of
asymptomatic individuals (Grade 1, level of evidence A).
(4) Screening for asymptomatic clinically significant carotid
bifurcation stenosis should be considered in certain
groups of patients with multiple risk factors that increase
the incidence of disease as long as the patients are fit forandwilling to consider carotid intervention if a significant
stenosis is discovered. The presence of a carotid bruit in
these patients increases the likelihood of a significant
stenosis (Grade 1, level of evidence B).
Such groups of patients include:
(a) Patients with evidence of clinically significant pe-
ripheral vascular disease regardless of age.
(b) Patients 65 years or older with a history of one or
more of the following atherosclerotic risk factors:
coronary artery disease, smoking, or hypercholester-
olemia. In general, the more risk factors present, the
higher the yield of screening should be expected.
5) Carotid screening may be considered in patients prior to
coronary artery bypass. This is most likely to be fruitful if
the patients are greater than 65, have left main disease or
a history of peripheral vascular disease. The strongest
indication for screening these patients from the data
available is to identify patients at high risk for periopera-
tive stroke. (Grade 2, level of evidence B)
6) Carotid screening is not recommended for patients with
abdominal aortic aneurysmwho do not fit into one of the
above categories (Grade 2, level of evidence B).
7) Carotid screening is not recommended for asymptom-
atic patients who have undergone prior head and neck
radiation. While the incidence of disease is increased in
this group of patients, the utility of intervention in the
absence of neurologic symptoms has not been clearly
established (Grade 2, level of evidence B).
I. RECOMMENDATIONS FOR SELECTION OF
CAROTID IMAGING MODALITIES
1) Carotid duplex ultrasound in an accredited vascular
laboratory is the initial diagnostic imaging of choice
for evaluating the severity of stenosis in both symp-
tomatic and asymptomatic patients. Under these
conditions unequivocal identification of stenosis of
50% to 99% in neurologically symptomatic patients
or 70% to 99% in asymptomatic patients is sufficient
to make a decision regarding intervention (Grade 1,
level of evidence A).
2) Carotid duplex ultrasound (CDUS) in an accredited
vascular laboratory is the imagingmodality of choice to
screen asymptomatic populations at high risk (Grade 1,
level of evidence B).
3) When CDUS is nondiagnostic, or suggests stenosis of
intermediate severity (50%-69%) in an asymptomatic
patient, additional imaging with magnetic resonance
angiography (MRA), computed tomographic angiog-
raphy (CTA), or digital subtraction angiography
(DSA) is required prior to embarking on any interven-
tion (Grade 1, level of evidence B).
4) When evaluation of the vessels proximal or distal to
the cervical carotid arteries is needed for diagnosis or
to plan therapy, imaging in addition to CDUS (ei-
ther CTA, MRA, or catheter angiography) is indi-
cated. CTA is preferable to magnetic resonance im-
aging/MRA for delineating calcium. When there is
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ing studies (CDUS, MRA, CTA), DSA is indicated
to resolve conflicting results. DSA is generally re-
served for situations where there is inconclusive
evidence of stenosis on less invasive studies or when
CAS is planned (Grade 1, level of evidence B).
(5) A postoperative duplex ultrasound, within 30 days, is
recommended to assess the status of the endarterecto-
mized vessel. In patients with 50% or greater stenosis
on this study, further follow-up imaging to assess pro-
gression or resolution is indicated. In patients with a
normal duplex and primary closure of the endarterec-
tomy site, ongoing imaging is recommended to iden-
tify recurrent stenosis. In patients with a normal duplex
ultrasound after patch or eversion endarterectomy,
further imaging of the endarterectomized vessel may
be indicated if the patient has multiple risk factors for
progression of atherosclerosis. There are insufficient
data to make recommendations on imaging after CAS
(Grade 2, level of evidence C). While the data in this
area are not robust concerning intervals for follow-up
imaging, the committee was unanimous in this recom-
mendation, recognizing that follow-up duplex ultra-
sound carries little risk.
(6) Imaging after CAS or CEA is indicated to follow
contralateral disease progression in patients with con-
tralateral stenosis 50%. In patients with multiple risk
factors for vascular disease, follow-up duplex may be
indicated with lesser degrees of stenosis. The likelihood
of disease progression is related to the initial severity of
stenosis (Grade 2, level of evidence C). While the data
in this area are not robust concerning intervals for
follow-up imaging, the committee was unanimous in
this recommendation, recognizing that follow up du-
plex ultrasound carries little risk.
III. RECOMMENDATIONS FOR MEDICAL
MANAGEMENT OF PATIENTS WITH
CAROTID ATHEROSCLEROSIS
(1) In patients with carotid artery stenosis, regardless of
whether or not intervention is planned, treatment of
hypertension, hypercholesterolemia, and efforts at smok-
ing cessation are recommended to reduce overall cardio-
vascular risk and risk of stroke. Targets are those defined
by the National Cholesterol Education Program guide-
lines (Grade 1, level of evidence A).
(2) Aggressive treatment of hypertension in the setting of
acute stroke is not recommended, however, treatment
of hypertension after this period has passed is associ-
ated with reduced risk of subsequent stroke. The target
parameters are not well defined (Grade 1, level of
evidence C).
(3) Treatment of diabetes with the goal of tight glucose
control has not been shown to reduce stroke risk, or
decrease complication rates after CEA, and is not rec-
ommended for these purposes (Grade 2, level of evi-
dence A).4) Anticoagulation is not recommended for the treatment
of transient ischemic attack or acute stroke unless there
is evidence of a cardioembolic source (Grade 1, level of
evidence B).
5) Antiplatelet therapy in asymptomatic patients with ca-
rotid atherosclerosis is recommended to reduce overall
cardiovascular morbidity although it has not been
shown to be effective in the primary prevention of
stroke (Grade 1, level of evidence A).
6) Antiplatelet therapy is recommended for secondary
stroke prevention: aspirin, aspirin combined with dipy-
ridamole and clopidogrel are all effective. Clopidogrel
combined with aspirin is not more effective than either
drug alone (Grade 1, level of evidence B).
7) Perioperative medical management of patients under-
going carotid revascularization should include blood
pressure control (140/80), beta blockade (HR 60-
80), and statin therapy (LDL100mg/dL) (Grade 1,
level of evidence B).
8) Perioperative antithrombotic therapy for CEA should
include aspirin, (81-325 mg) (Grade 1, level of evi-
dence A). The use of clopidogrel in the perioperative
period should be decided on a case by case basis (Grade
2, level of evidence B).
9) Perioperative antithrombotic management of CAS pa-
tients should include dual antiplatelet therapy with
aspirin and either ticlopidine or clopidogrel. Dual an-
tiplatelet therapy should be initiated at least 3 days
prior to CAS and continued for 1 month and aspirin
therapy should be continued indefinitely (Grade 1,
level of evidence C).
V. RECOMMENDATIONS REGARDING CEA
AND CAS TECHNIQUE
1) Patch angioplasty or eversion endarterectomy is rec-
ommended over primary closure to reduce the early
and late complications of CEA (Grade 1, level of
evidence A).
2) Use of an embolic protection device (proximal or distal
occlusion, distal filter) is recommended during CAS to
reduce the risk of cerebral embolization (Grade 1, level
of evidence B).
. RECOMMENDATIONS FOR SELECTING
THERAPY
1) For neurologically symptomatic patients with stenosis
50% or asymptomatic patients with stenosis 60% di-
ameter reduction optimal medical therapy is indicated.
There are no data to support either CAS or CEA in this
patient group (Grade 1, level of evidence B).
2) In the majority of patients with carotid stenosis who are
candidates for intervention, CEA is preferred to CAS for
reduction of all cause stroke and periprocedural mortality
(Grade 1, level of evidenceB).Data fromCREST suggest
that patients 70 years of age may be better treated by
CAS. These data need further confirmation.
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60% diameter stenosis, should be considered for
CEA for reduction of long-term risk of stroke provided
the patient has a 3- to 5-year life expectancy and
perioperative stroke/death rates can be equal to or
3% (Grade 1, level of evidence A).
(4) CEA is preferred over CAS in patients 70 years of
age, with long (15 mm) lesions, preocclusive ste-
nosis, or lipid-rich plaques that can be completely
removed safely by a cervical incision in patients who
have a virgin, nonradiated neck (Grade 1, level of
evidence A).
(5) CAS is preferred over CEA in symptomatic patients
with 50% stenosis and prior ipsilateral operation,
tracheal stoma, external beam irradiation resulting in
fibrosis of the tissues of the ipsilateral neck, or prior
cranial nerve injury and lesions that extend proximal to
the clavicle or distal to the C2 vertebral body (Grade 2,
level of evidence B).
(6) CAS is preferred over CEA in symptomatic patients
with 50% stenosis and severe uncorrectable CAD,
CHF, or COPD (Grade 2, level of evidence C). In
making this a grade 2 recommendation, the commit-
tee recognized the difficulty in clearly defining this
group of individuals, both in terms of symptomatol-
ogy and risk assessment and acknowledged the po-
tential increased role of aggressive medical manage-
ment as primary therapy in this high risk group.
(7) Neurologically asymptomatic patients deemed “high
risk” for CEA should be considered for primary medi-
cal management. CEA can be considered in these
patients only with evidence that perioperative morbid-
ity andmortality is3%. CAS should not be performed
in these patients except as part of an ongoing clinical
trial (Grade 1, level of evidence B).
(8) There are insufficient data to recommend CAS as pri-
mary therapy for neurologically asymptomatic patients
with 70% to 99% diameter stenosis. Data from CREST
suggest that in properly selected asymptomatic pa-
tients, CAS is equivalent to CEA in the hands of
experienced interventionalists. Operators and institu-
tions performing CAS must exhibit expertise sufficient
to meet the previously established American Heart
Association guidelines for treatment of patients with
asymptomatic carotid stenosis. Specifically, the com-
bined stroke and death rate must be below 3% to
ensure benefit for the patient (Grade 2, level of evi-
dence B).
VI. UNUSUAL CONDITIONS ASSOCIATED
WITH CAROTID STENOSIS
A. Recommendations for management of acute
neurologic syndromes
(1) Patients who present within 6 hours of the onset of
stroke should be considered for acute intervention to
reduce the ultimate neurologic deficit. Interventionsmay include local or systemic thrombolysis (Grade 1,
level of evidence A). The role of endoluminal mechan-
ical lysis or extraction remains to be defined.
2) Patients who present with fixed neurologic deficit of
more than 6 hours duration should be considered for
CEA once their condition has been stabilized. CEA
should be performed within 2 weeks of the neurologic
event (Grade 1, level of evidence B).
3) Patients who present with repetitive (crescendo)
episodes of transient cerebral ischemia unresponsive
to antiplatelet therapy should be considered for ur-
gent CEA. The risk of intervention is increased over
elective surgery for neurologic symptoms, but not as
much as for patients with stroke in evolution. CEA is
preferred to CAS in these patients based on the
presumptive increased embolic potential of bifurca-
tion plaque in this clinical situation (Grade 1, level of
evidence C).
4) For acute stroke after CEA, emergent imaging (ul-
trasound or fast CTA) is indicated to evaluate the
endarterectomy site. When imaging suggests throm-
bosis, is indeterminate or not available, immediate
operative re-exploration is indicated (Grade 1, level
of evidence B).
5) When the endarterectomy site is patent, other mo-
dalities such as CT and angiography should be used
to better identify the cause of the stroke. If CT
excludes intracranial hemorrhage, anticoagulation is
reasonable until a definitive decision regarding the
appropriate diagnosis and therapy can be made
(Grade 2, level of evidence C). While the committee
acknowledged the lack of robust data in this small
group of patients, it was unanimous in its endorse-
ment of this recommendation based on the data
available and the low likelihood that new data would
emerge in the near future.
6) No firm recommendations can be made on treat-
ment of stent thrombosis associated with CAS. It is
reasonable to attempt to restore patency by use of
chemical lysis or clot extraction (Grade 2, level of
evidence C). While the committee acknowledged
the lack of robust data in this small group of patients,
it was unanimous in its endorsement of this recom-
mendation based on the data available and the low
likelihood that new data would emerge in the near
future.
. Recommendations for management of
symptomatic internal carotid occlusion
1) Patients with known internal carotid occlusion and
persistent ipsilateral neurologic symptoms can be
treated by endarterectomy of the common and exter-
nal carotid artery with transection and ligation of the
internal carotid origin. The addition of oral anticoag-
ulation is likely to reduce the rate of recurrent stroke
(Grade 1, level of evidence C).
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dissection:
(1) Patients with carotid dissection should be initially treated
with antithrombotic therapy (antiplatelet agents or anti-
coagulation) (Grade 1, level of evidence C).
(2) Patients who remain symptomatic on medical therapy
may be considered for intervention. While there are in-
sufficient data to make firm recommendations, the com-
mittee unanimously felt that balloon angioplasty and
stenting is currently preferred over open surgery after
failed medical management (Grade 2, level of evi-
dence C).
D. Recommendations for management of combined
carotid and coronary disease
(1) Patients with symptomatic carotid stenosis will benefit
from carotid endarterectomy prior to or concomitant mwith coronary artery bypass graft. The timing of the
intervention depends on clinical presentation and in-
stitutional experience (Grade 1, level of evidence B).
2) Patients with severe bilateral asymptomatic carotid steno-
sis (including stenosis and contralateral occlusion) should
be considered for carotid endarterectomy prior to or
concomitant with coronary artery bypass graft (Grade 2,
level of evidence B).
The above recommendations are meant to inform the
ractice of physicians and surgeons caring for patients with
arotid bifurcation stenosis. They are unanimously supported
y all members of the Guidelines Committee, who believe
hat they represent the current best practice based on availa-
le data. The Committee recognizes that these guidelines are
ikely to be a “living document” that will be altered in the
uture as techniques are further refined, technology develops,
edical therapy improves, and new data emerges.
